Hyperphosphatemia is associated with a
|
|
- Amber George
- 6 years ago
- Views:
Transcription
1 TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular events in patients with chronic kidney disease (CKD). For patients who cannot control their serum phosphate levels adequately with diet, agents that limit gastrointestinal phosphate uptake are indicated. The use of phosphate-binding agents has changed over the years as more is learned about the mechanisms that underlie the clinical effects of hyperphosphatemia and pharmacologic effects of the agents themselves. Calcium-containing oral agents largely replaced aluminum-based products because the latter, although effective, were associated with serious toxicities. A growing body of evidence suggests that calcium-based phosphate binders may increase the calcium load in patients with CKD, accelerating arterial calcification and increasing cardiovascular risk. Sevelamer hydrochloride and lanthanum carbonate are non calcium-containing phosphate binders currently available for the management of hyperphosphatemia. In addition, several new therapeutic approaches are emerging as the understanding of vascular calcification evolves. (Adv Stud Med. 27;7(5): ) *This article is based on content from a presentation developed as part of a continuing medical education lecture series, which comprised presentations held in various US cities throughout 26. Secretary General, International Society of Nephrology s Commission on Acute Renal Failure, Emeritus Professor of Medicine, Chief, Division of Nephrology, Oregon Health and Science University School of Medicine, Portland, Oregon. Robert G. Luke Chair in Nephrology, Professor of Medicine, Chief, Division of Nephrology, Bone and Mineral Metabolism, Director, General Clinical Research Center, University of Kentucky, Lexington Kentucky. Address correspondence to: George A. Porter, MD, FACP, Chief, Division of Nephrology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR porterg@ohsu.edu. Hyperphosphatemia is associated with a range of complications in patients with chronic kidney disease (CKD), such as hyperparathyroidism, osteodystrophy, anemia, and soft-tissue calcification. 1 The need for effective management of serum phosphate levels in end-stage renal disease (ESRD) has long been recognized as a treatment priority, and various management strategies have been used over the years. When controlling phosphate intake by dietary restriction and dialysis are not sufficient, binders that reduce intestinal absorption of phosphate are the mainstay of treatment to control high serum phosphorus. 2 Aluminum-based agents were among the first phosphate-binding agents used. Although they were effective in reducing serum phosphate levels, they also were associated with serious toxicities. 3-6 Calcium-containing oral preparations replaced the aluminum-based binders and have been used extensively since the late 198s and early 199s. 7 However, recent evidence suggests that calciumbinding agents, by contributing an excess calcium load, may exacerbate vascular calcification. 8 As discussed in the article by Drs Middleton and Malluche earlier in this monograph, both hyperphosphatemia and vascular calcification are associated with increased risk of cardiovascular mortality in patients with ESRD. 9,1 Thus, alternatives to calcium-containing preparations may be important to reducing the cardiovascular risk in this vulnerable population. Sevelamer hydrochloride and lanthanum carbonate are calcium- and aluminum-free agents with proven efficacy in the reduction of serum phosphate levels. Preliminary evidence indicates that these agents are not associated with increased vascular calcification. This paper will compare the safety, efficacy, and tolerability profiles of calcium binders, sevelamer, and lanthanum. Data regarding rates of arterial calcification in patients using these agents will be discussed in the 146 Vol. 7, No. 5 May 27
2 context of current and future options for the management of hyperphosphatemia. PHOSPHATE BINDERS AND BONE DISEASE In the 198s, the increase in parathyroid hormone (PTH) and decrease in calcitriol (1,25-hydroxyvitamin D 3 ) seen in patients with CKD were associated with mixed uremic osteodystrophy in a high percentage of patients. 11 A smaller proportion of patients presented with more severe forms of renal osteodystrophy, including predominant hyperparathyroid bone disease or aluminum-related osteomalacia. However, by the early 199s, the incidence of adynamic bone disease and osteomalacia decreased with the virtual elimination of aluminum-based binder use. 7 After 1995, there was an increase in the prevalence of adynamic bone disease without evidence of aluminum toxicity. This increase occurred at the same time as the increased use of calcium-based binders. The increased calcium load resulting from these agents suppressed PTH, particularly when calcium salts were used together with calcitriol supplementation. Distinguishing between adynamic bone disease and hyperparathyroid bone disease is important because the management approach differs depending on the diagnosis. 7 Furthermore, it may be important to balance the calcium turnover present in bones of patients with CKD to minimize the risk of soft-tissue calcification. 12 EVOLUTION OF PHOSPHATE-BINDING AGENTS ALUMINUM-CONTAINING PHOSPHATE BINDERS Prior to 1985, aluminum-containing phosphate binders were standard treatment for patients with ESRD, and their efficacy in reducing phosphate absorption was good. 1 However, plasma aluminum levels gradually increase in patients taking aluminum hydroxide, a common formulation. The absorbed aluminum was associated with serious toxicities, including osteomalacia, bone and muscle pain, iron-resistant microcytic anemia, and neurologic abnormalities. As a result of these toxicities, the aluminum-based binders are rarely used as the primary phosphate binder. 3-6 CALCIUM-CONTAINING PHOSPHATE BINDERS Calcium-based binders became the most frequently used of the phosphate-binding class in the 198s and 199s; however, use of these agents may contribute to progressive vascular calcification, indirectly contributing to mortality. 13 Both calcium carbonate and calcium acetate are effective in reducing intestinal phosphorus absorption and in lowering serum phosphate concentrations. 14 Calcium carbonate is weakly soluble in water and binds phosphate poorly at neutral ph. The gastrointestinal solubility of calcium carbonate preparations can vary, and nondisintegrating tablets have been seen on abdominal radiographs, suggesting minimal intestinal uptake. 14 Calcium acetate is soluble at neutral ph and is able to bind phosphate. Constipation, reported with calcium carbonate, occurs less often with calcium acetate; however, calcium acetate is infrequently tolerated, and patient compliance may be worse than with calcium carbonate. 14 Although lower doses may be required to control hyperphosphatemia, calcium acetate tends to produce hypercalcemia, especially when administered with calcitriol; however, hypercalcemia occurs more often with calcium carbonate than with calcium acetate. 14 A study designed to determine whether modulating bone turnover affected arterial calcification found that calcium binders may contribute to softtissue calcification. Fifty-eight nondiabetic patients with ESRD who were undergoing hemodialysis for at least 1 year were evaluated for the extent of arterial calcifications using ultrasound. 8 Although calcium carbonate was the only phosphate binder being used by the patients at study entry, 33 had taken aluminum hydroxide in the past. The extent of calcification at multiple sites was ranked using a scale ranging from (no calcifications) to 4 (generalized calcifications present in all arterial segments examined). Higher arterial calcification scores were positively correlated with age (P <.1), calcium carbonate phosphate-binder dose (P <.1), aluminum-stained bone surfaces (P <.37), and decreased osteoblast surfaces (P <.1). 8 Hence, excessive calcium load, as well as aluminum, was associated not only with low bone turnover and adynamic bone disease, but also with increased softtissue calcification. ALUMINUM- AND CALCIUM-FREE ALTERNATIVES Currently, sevelamer hydrochloride and lanthanum carbonate are the only aluminum- and calcium-free agents available. They are increasingly used in the ESRD population. Johns Hopkins Advanced Studies in Medicine 147
3 SEVELAMER HYDROCHLORIDE Sevelamer hydrochloride is an effective, aluminumand calcium-free phosphate binder. 2 It also lowers serum low-density lipoprotein (LDL) cholesterol levels, although the clinical significance of this effect has not been demonstrated. Treatment with sevelamer has been shown to stabilize vascular calcification. 15 Use of this agent is limited by expense, potential gastrointestinal upset, and requisite high pill burden. 16,17 An open-label, randomized study of 19 adult patients new to hemodialysis compared the effects of sevelamer hydrochloride and calcium phosphate binders on arterial calcification. 18 Over the 18-month study duration, both agents decreased serum phosphate levels to a similar extent. However, patients receiving sevelamer hydrochloride had significantly lower mean corrected calcium (P <.1), higher immunoreactive PTH (P =.5), higher PTH (1-84) (P =.3), lower total cholesterol (P =.3), and lower LDL cholesterol (P =.3). A comparison of the effects of phosphate binders on cardiovascular calcification was conducted over 52 weeks in 114 adult patients on hemodialysis. In this open-label study, patients received either sevelamer hydrochloride or calcium carbonate. 19 Overall reductions in serum phosphate were similar in the 2 treatment groups. However, patients receiving calcium carbonate had significant increases in coronary artery calcification (median increase, 34%; P <.1) and aortic calcification (32%; P <.1) that were not seen in the patients treated with sevelamer hydrochloride (Figure 1). In addition, significantly greater calcification was observed in patients whose serum phosphate levels were above the median value (P <.1 for both treatment groups). As recently reported, patients in this open-label study were followed for the secondary endpoint of allcause mortality. 2 At the end of the 44-month followup, 34 deaths were recorded: 11 in the sevelamer hydrochloride group and 23 in the calcium binder group. Coronary artery calcium scores were not significantly different between groups at baseline. After adjustment for age, race, gender, and the presence of diabetes, baseline coronary artery calcium score was a significant predictor of mortality (P =.2). In addition, choice of phosphate binder was also a predictor of mortality. Patients treated with calcium binders had a greater risk of death compared to those treated with sevelamer hydrochloride (P =.16; hazard ratio, 3.1; confidence interval, ). LANTHANUM CARBONATE Lanthanum carbonate is an alternative to sevelamer hydrochloride that also is free of calcium and aluminum. 1,21 This agent has no known biotransformation and does not have any known local or systemic drug interactions. For example, this agent does not interact with warfarin, metoprolol, or digoxin. Lanthanum carbonate does not cross the blood-brain barrier and thus has a low potential for central nervous system effects. 22 The efficacy of lanthanum carbonate is similar to that of standard therapy in reducing phosphate levels. An open-label, parallel-group active comparator-controlled trial involving 1566 patients evaluated longterm (2-year) safety and tolerability of lanthanum carbonate. 21 Patients were included if they were 18 years of age or older and were on maintenance hemodialysis 3 times weekly for at least 2 months immediately prior to the study. Efficacy, having previously been demonstrated, was a secondary endpoint. Lanthanum carbonate treatment was initiated at 75 or 15 mg/d and titrated according to serum phosphate levels. Patients randomized to standard therapy resumed their prestudy phosphate binder and dosing regimen after the washout period. The serum phosphate levels in both treatment groups decreased during the titration period and remained stable throughout the study. 21 Serum phosphate levels were Figure 1. Change in Coronary Artery Calcification According to Phosphorus (P) Exposure Median change in coronary calcification Sevelamer Calcium carbonate P <median P >median There were significant changes between patients above and below the median phosphorus value within each group (P <.1 for both groups). Reprinted with permission from Braun et al. Clin Nephrol. 24;62: Vol. 7, No. 5 May 27
4 adequately controlled ( 5.9 mg/dl) in similar percentages of patients in each treatment group throughout maintenance treatment (Figure 2). At 24 months, 46% of those in the lanthanum carbonate group and 49% of patients in the standard therapy group had controlled levels (P =.5). Serum calcium levels decreased with lanthanum carbonate treatment during the titration period (Figure 3). 21 Levels were consistently lower in the lanthanum carbonate group than with standard therapy throughout the study. Serum calcium levels were not Figure 2. Lanthanum Carbonate Versus Standard Therapy: Serum Phosphate Levels Serum phosphate, mg/dl Study week Lanthanum carbonate Standard therapy Study month Points represent mean ± 95% confidence interval. Reprinted with permission from Finn. Clin Nephrol. 26;65: significantly different between groups at baseline. Serum calcium decreased in the lanthanum carbonate group during titration and remained consistently lower than those in the standard therapy group throughout the 2-year study. Mean PTH levels in patients taking lanthanum carbonate reached the National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommended range (15 3 pg/ml) during titration and remained stable over the study duration. PTH levels in the standard therapy group remained below the recommended range for the entire study period. (Figure 4). 21 Serum calcium-phosphorus product (Ca x P) levels decreased during titration and then remained stable in both groups. Analysis of data from an open-label extension of this study and 3 others showed that treatment with lanthanum carbonate maintained control of serum phosphate and Ca x P, and was well tolerated, for up to 6 years of treatment. 23 The most commonly reported adverse events were nausea, diarrhea, and flatulence. 22 No adverse effects on liver enzyme function were reported during 2 years of follow-up. 24 The route of elimination for lanthanum carbonate is via the liver. Adverse effects on liver histology have not been detected in normal and uremic animals given doses of lanthanum carbonate up to 17 times the human clinical dose of 3 g per day. This lack of effect on liver histology is thought to be attributable to the compartmentalization of lanthanum carbonate into lysosomes and transport to the bile for elimination. 25 Figure 3. Lanthanum Carbonate Versus Standard Therapy: Serum Calcium Levels Serum calcium, mg/dl Study week Lanthanum carbonate Standard therapy Study month Points represent mean ± 95% confidence interval. Reprinted with permission from Finn. Clin Nephrol. 26;65: NEW TARGETS FOR THERAPY Increasing understanding of the molecules that regulate phosphate metabolism as well as those that are involved in arterial calcification provide potential new therapeutic targets to reduce mortality and morbidity associated with CKD. Studies of rare disorders associated with phosphate wasting have led to the discovery of phosphatonins. 26 These molecules include fibroblast growth factor (FGF)-23, secreted frizzled-related protein-4, matrix extracellular phosphoglycoprotein, and FGF-7, which decrease renal tubular sodium-dependent phosphate reabsorption, both in vivo and in vitro. These compounds also decrease intestinal phosphate absorption and retention of phosphate by the body. 26 However, in contrast to PTH, FGF-23 decreases renal C 1 α-hydroxylase. Phosphatonins may provide new insight into the molecular controls of phosphate Johns Hopkins Advanced Studies in Medicine 149
5 Figure 4. Lanthanum Carbonate Versus Standard Therapy: PTH Levels Serum PTH, ng/l Screening in CKD and have the potential to be useful tools in managing hyperphosphatemia. Several proteins have been identified that inhibit ectopic calcification in vivo. These include fetuin-a, matrix Gla protein, and osteopontin. These proteins are expressed in atherosclerotic plaques and may provide another therapeutic target to reduce cardiovascular risk resulting from soft-tissue calcification. 27 CONCLUSIONS Study week Lanthanum carbonate Standard therapy Study month PTH = parathyroid hormone. Reprinted with permission from Finn. Clin Nephrol. 26;65: When patients with CKD develop hyperphosphatemia, this is associated with secondary hyperparathyroidism and elevated Ca x P. Moreover, hyperphosphatemia is an independent risk factor for cardiovascular morbidity and mortality. Traditionally, aluminum-based phosphate binders were used to reduce intestinal absorption of dietary phosphate. However, the toxicity associated with these binders prompted a shift to using calcium-based formulations. Recent evidence suggests that calcium-based phosphate binders contribute to the overall calcium body burden, increasing arterial calcification and cardiovascular risk. Two alternatives to calcium-based phosphate binders, sevelamer hydrochloride and, more recently, lanthanum carbonate, have been developed. Sevelamer hydrochloride and lanthanum carbonate are safe and effective for reducing serum phosphorus levels and may reduce arterial calcification. Greater understanding of the roles of phosphatonins and inhibitors of arterial calcification may provide additional approaches to reducing the impact of soft-tissue calcification in this population. REFERENCES 1. Albaaj F, Hutchinson AJ. Hyperphosphatemia in renal failure: causes, consequences, and current management. Drugs. 23;63: Malluche HH, Mawad H. Management of hyperphosphatemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant. 22; 17: Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure. N Engl J Med. 1984;311: Faugere MC, Arnala IO, Ritz E, Malluche HH. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med. 1986;17: Malluche HH, Faugere MC, Friedler RM, et al. Calcitriol, parathyroid hormone, and accumulation of aluminum in bone in dogs with renal failure. J Clin Invest. 1987;79: Malluche HH, Faugere MC. Aluminum-related bone disease. Blood Purif. 1988;6: Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan into the fire? Nephrol Dial Transplant. 24;199(suppl 1):i9-i London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 24;15: Tonelli M, Sacks F, Gao Z, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Cholesterol and Recurrent Events Trial Investigators. Circulation. 25;112: London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 23;18: Malluche HH, Faugere MC. Renal bone disease 199: an unmet challenge for the nephrologist. Kidney Int. 199;38: Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46: Goodman WG, Goldin J, Kuizon BD, et al. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2;342: Loghman-Adham M. Phosphate binders for control of phosphate retention in chronic renal failure. Pediatr Nephrol. 15 Vol. 7, No. 5 May 27
6 1999;13: Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Treat to Goal Working Group. Kidney Int. 22;62: Ritz E, Hergesell O. Compounds in development to combat hyperphosphatemia. Expert Opin Invest Drugs. 21;1: Renagel tablets (sevelamer hydrochloride) 4 and 8 mg [prescribing information]. Cambridge, Mass: Genzyme Corporation; October Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 25;68: Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonatephosphorus metabolism and cardiovascular calcification. Clin Nephrol. 24;62: Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. 27;71: Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. SPD Lanthanum Study Group. Clin Nephrol. 26;65: Fosrenol (lanthanum carbonate) [prescribing information]. Wayne, Pa: Shire US Inc; November Hutchinson A, Pratt R. Evidence for the long-term safety and tolerability of lanthanum carbonate. SPD45-39 Lanthanum Carbonate Group. Paper presented at: 38th Annual Meeting of the American Society of Nephrology; November 8-13, 25; Philadelphia, Pa. 24. Siami GA, Wilson RJ, Finn WF. No evidence for hepatotoxicity after 2 years of lanthanum carbonate therapy. SPD45-37 Lanthanum Study Group. Poster presented at: 38th Annual Meeting of the American Society of Nephrology; November 8-13, 25; Philadelphia, Pa. 25. Yang Z, Schryvers D, Roels F, et al. Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc. 26;223: Berendt TJ, Schiavi S, Kumar R. Phosphotonins and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol. 25;289:F117-F Dellegrottaglie S, Sanz J, Rajagopalan S. Vascular calcification in patients with chronic kidney disease. Blood Purif. 26;24: Johns Hopkins Advanced Studies in Medicine 151
Normal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationEffect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
Research Article Effect of lanthanum and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease P. Thomas Scaria, Reneega Gangadhar 1, Ramdas Pisharody 2 ABSTRACT Departments
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationA new era in phosphate binder therapy: What are the options?
http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationSevelamer hydrochloride: a calcium- and metal-free phosphate binder
DRUG PROFILE Sevelamer hydrochloride: a calcium- and metal-free phosphate binder Anthony J Bleyer & James Balwit Author for correspondence Wake Forest University School of Medicine, Section on Nephrology,
More informationChronic kidney disease (CKD) and the
BONE COPLICATIONS AND CALCIFICATION OF SOFT TISSUES IN CHRONIC KIDNEY DISEASE * John P. iddleton, D, and Hartmut H. alluche, D, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson- Zachrisson,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationTreatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD
More informationLanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding
Renal Failure, 34(3): 263 270, (2012) Copyright Informa Healthcare USA, Inc. ISSN 0886-022X print/1525-6049 online DOI: 10.3109/0886022X.2011.649657 Lanthanum Carbonate Reduces Urine Phosphorus Excretion:
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationManagement of CKD. Goce Spasovski, R. Macedonia
Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD
More informationLiterature Scan: Phosphate Binders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationBenefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials
Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C. Craig, MBChB, PhD, Grahame J.
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationDEGREE (if applicable)
OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018) BIOGRAPHICAL SKETCH DO NOT EXCEED FIVE PAGES. NAME: Malluche, Hartmut H. era COMMONS USER NAME (credential, e.g., agency login):
More informationRandomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients
Article Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients Rudolf P. Wüthrich,* Michel Chonchol, Adrian Covic, Sylvain Gaillard, Edward Chong, and James A. Tumlin
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationLevel 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor
chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationCost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients
original article http://www.kidney-international.org & 2007 International Society of Nephrology Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis
More informationTreatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)
Kidney International, Vol. 65 (2004), pp. 1914 1926 Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study) WAJEH Y. QUNIBI,ROBERT E. HOOTKINS,LAVETA
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationDraft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)
Draft Labeling Package Insert Not Actual Size BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) DESCRIPTION: Full Size: Each opaque capsule with a white cap and white body is spin printed
More informationReversal of adynamic bone disease by lowering of dialysate calcium
http://www.kidney-international.org & 26 International Society of Nephrology original article Reversal of adynamic bone disease by lowering of dialysate calcium A Haris 1, DJ Sherrard 2 and G Hercz 3 1
More informationTHE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION
THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationTenapanor, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers
, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers David Rosenbaum, 1 Susanne Johansson, 2 Björn Carlsson, 2 Andrew G Spencer, 1 Bergur Stefansson, 2 Mikael
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More informationAPPLYING KDIGO GUIDELINES TO
Knowledge Exchange 2016 APPLYING KDIGO GUIDELINES TO CLINICAL PRACTICE MARKUS KETTELER, MD, FELLOW OF THE EUROPEAN RENAL ASSOCIATION DIVISION OF NEPHROLOGY, KLINIKUM COBURG COBURG, GERMANY Date of preparalon:
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationTITLE: Sevelamer Hydrochloride for the Treatment of Patients with Chronic Kidney Disease: A Review of the Clinical Effectiveness
TITLE: Hydrochloride for the Treatment of Patients with Chronic Kidney Disease: A Review of the Clinical Effectiveness DATE: 08 September 2009 CONTEXT AND POLICY ISSUES: Patients with end-stage chronic
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationC ardiovascular disease (CVD) and stroke are the main causes of morbidity and
Original Article DOI: 10.22088/cjim.9.4.347 Risk factors associated with aortic calcification in hemodialysis patients Alireza PeyroShabani 1 Mehrdad Nabahati (MD) 2, 3 MohammadAli Saber Sadeghdoust (MD)
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More informationParsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW
Parsabiv (etelcalcetide) NEW PRODUCT SLIDESHOW Introduction Brand name: Parsabiv Generic name: Etelcalcetide Pharmacological class: Calcimimetic Strength and Formulation: 2.5mg/0.5mL, 5mg/mL, 10mg/2mL;
More informationNOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationIntroduction and rationale. Yoshitaka Isaka 1 Hideki Fujii 2 Yoshihiro Tsujimoto 3 Satoshi Teramukai 4 Takayuki Hamano 5
https://doi.org/10.1007/s10157-018-1547-5 ORIGINAL ARTICLE Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients
More informationThe effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
Nephrol Dial Transplant (2011) 26: 1615 1621 doi: 10.1093/ndt/gfq598 Advance Access publication 4 October 2010 The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral
More informationParsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1
Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative
More informationCowen Healthcare Conference March 12, 2018
Cowen Healthcare Conference March 12, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationSlowing the Progression of Vascular Calcification in Hemodialysis
Slowing the Progression of Vascular Calcification in Hemodialysis J Am Soc Nephrol 14: S310 S314, 2003 GLENN M. CHERTOW Division of Nephrology, Department of Medicine, University of California San Francisco,
More informationChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationEffectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients
Open Access Journal of Journal of Parathyroid Disease 2017,5(1),17 24 http://www.jparathyroid.com Original Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationMalnutrition and Role of Nutrition in BMD:CKD
Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers STAGED
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More informationSecondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationPROTECTING HEART, VESSELS, AND BONE: NEW WAYS TO CONTROL PHOSPHORUS
PROTECTING HEART, VESSELS, AND BONE: NEW WAYS TO CONTROL PHOSPHORUS This symposium took place on 22 th May 2016 as part of the European Renal Association - European Dialysis and Transplant Association
More informationMetabolic Bone Disease (Past, Present and Future Challenges in the Management)
Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading
More informationPediatric Nutrition and Kidney Disease
Pediatric Nutrition and Kidney Disease Loai Eid, MD, MSHS, FAAP Consultant Pediatric Nephrologist Pediatric Nephrology & Hypertension Division Chief Dubai Hospital - DHA 26 th October, 2017 Objectives
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationKidney Disease. Chronic kidney disease (CKD) requiring dialysis. The F.P. s Role in the Management of Chronic. Stages
Focus on CME at McMaster University The F.P. s Role in the Management of Chronic Kidney Disease By David N. Churchill, MD, FRCPC, FACP Presented at McMaster University CME Half-Day in Nephrology for Family
More informationSecondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management
Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Complete this course and earn 1 CME POINT Dr. HO Chung Ping MBBS (HK), MRCP, FRCP (Glas, Edin), FHKCP,
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More informationKDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke
CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke Unité 1088 de l Inserm UFR de Médecine et de Pharmacie Jules Verne University of Picardie Amiens, France Poten2al conflicts of interest Research support:
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationMineral metabolism is modulated by
REGULATION OF PHOSPHATE IN HEALTH AND DISEASE * William F. Finn, MD, and Hartmut H. Malluche, MD, FACP ABSTRACT As is true of many physiologically critical systems, metabolism is a highly regulated process.
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationLong-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism Kazunori Nakayama 1, 2, Kazushi Nakao 1, 2, Yuji Takatori 1,
More information